Cargando…

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.

Current standard adjuvant therapies for early breast cancer include tamoxifen and chemotherapy, depending on the disease prognosis and menopausal status. Luteinizing hormone-releasing hormone (LHRH) analogues offer a different approach to the management of early breast cancer in pre- and perimenopau...

Descripción completa

Detalles Bibliográficos
Autor principal:	Jonat, W.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062750/ https://www.ncbi.nlm.nih.gov/pubmed/9741781

Ejemplares similares

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
por: Lu, Yen-Shen, et al.
Publicado: (2021)

Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
por: Kaufmann, M.
Publicado: (1998)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.
por: Maynard, P. V., et al.
Publicado: (1979)

Bilateral injection-site granuloma by subcutaneous administration of luteinizing hormone-releasing hormone analogue: a case report
por: Kitazawa, Riko, et al.
Publicado: (2009)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Incidence Rate of Injection-Site Granulomas Resulting from the Administration of Luteinizing Hormone-Releasing Hormone Analogues for the Treatment of Prostatic Cancer
por: Shiota, Masaki, et al.
Publicado: (2007)

Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
por: Angulo, J. C., et al.
Publicado: (2022)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model
por: Garg, Himani, et al.
Publicado: (2018)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

Application of luteinizing hormone-releasing hormone–ferrosoferric oxide nanoparticles in targeted imaging of breast tumors
por: Nian, Di, et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Polymorphisms, endogenous hormone levels and familial breast cancer risk in premenopausal women
por: Walker, K, et al.
Publicado: (2010)

Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis
por: Jiang, Mengjie, et al.
Publicado: (2021)

Topographical localization of the receptors for luteinizing hormone- releasing hormone on the surface of dissociated pituitary cells
Publicado: (1977)

Early preclinical work with gonadotropin-releasing hormone analogues
por: Gordon, Keith
Publicado: (2023)

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
por: Zhang, Xianlu, et al.
Publicado: (2023)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone
por: Lambalk, Cornelis B.
Publicado: (2023)

Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women
por: Bernhardt, Sarah M., et al.
Publicado: (2016)

Effects of luteinizing hormone-releasing hormone and arginine-vasotocin on the sperm-release response of Günther's Toadlet, Pseudophryne guentheri
por: Silla, Aimee J
Publicado: (2010)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Detection of urinary luteinizing hormone in Japanese black cows after administration of gonadotropin-releasing hormone
por: MIYAZAKI, Tamako, et al.
Publicado: (2021)

Cigarette Smoking and Effects on Hormone Function in Premenopausal Women
por: Windham, Gayle C., et al.
Publicado: (2005)

Meningiomas in Premenopausal Women: Role of the Hormone Related Conditions
por: Maiuri, Francesco, et al.
Publicado: (2020)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer
por: Anderson, Richard A., et al.
Publicado: (2022)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report
por: ANDA, Takeo, et al.
Publicado: (2014)

A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer
por: Zhu, Shengsheng, et al.
Publicado: (2016)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

Effects of growth hormone administration on luteinizing hormone secretion in healthy older men and women
por: Muniyappa, Ranganath, et al.
Publicado: (2017)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i174nd5hni4fgrd8sff9k05904